Portuguese pharma firm says best practice followed in French drug trial

January 15, 2016

Portuguese pharmaceutical company Bial insisted Friday that it had followed "international best practice" in a French drugs trial that has left one person brain-dead and five others hospitalised.

The company said in a statement it had followed "the applicable legislation" and that it would cooperate with the investigation underway to "determine in a rigorous and exhaustive manner" what happened.

The six victims, all men aged 28 to 49, had repeatedly taken the medication developed by Bial, which is intended to treat pain and such as anxiety.

"Our principal concern, at the moment, is taking care of participants in the trial," Bial said, particularly those who have been hospitalised.

The manufacturer said the product was an "inhibitor of the enzyme FAAH", or fatty acid amide hydrolase, which was being developed with "respect since the start for international best practice, with pre-clinical trials carried out, notably with respect to toxicology".

"This trial was approved by the regulatory authorities and the French ethics committee," the company said.

It added: "108 volunteers in good health participated in the testing of this new molecule without developing any adverse reaction, either moderate or serious."

French Health Minister Marisol Touraine had earlier said 90 people had been given the substance in variable doses.

Based in northern Portugal near the town of Porto, Bial says on its website that it is the country's largest pharmaceutical company, founded in 1924 with a presence in 58 countries.

It has produced treatments for a range of ailments including problems with the nervous system and cardiovascular health, as well as antibiotics and anti-allergens.

The drug test in France has been carried out since the summer by Biotral, a medical research company approved by the ministry, on behalf of the Portuguese .

Explore further: Botched French drug trial leaves 1 brain dead, 5 in hospital

Related Stories

Botched French drug trial leaves 1 brain dead, 5 in hospital

January 15, 2016
One man was brain dead and three others faced possible permanent brain damage after volunteering to take part in a trial for a painkiller and anxiety medication based on a natural brain compound similar to the active ingredient ...

Drugs trial tragedies: a rarity

January 15, 2016
Drugs trial tragedies like that reported in France on Friday which left one person brain dead and three others facing irreversible brain damage are a rarity, experts say.

Drug approval: How does it work?

January 15, 2016
The process of vetting experimental drugs is designed, with safety in mind, to be cautiously meticulous.

New cancer fears in France over breast implants (Update)

March 17, 2015
France's national cancer institute said on Tuesday there was a "clearly established link" between a rare form of cancer and a certain type of breast implant, as the health minister sought to allay fears.

Renault shares plunge after anti-fraud raids over emissions

January 14, 2016
Shares in Renault dived Thursday after French anti-fraud units conducted searches at the carmakers' facilities, prompted by the Volkswagen emissions scandal. They then recovered somewhat after the company said tests had not ...

Brazil authorizes dengue vaccine

December 28, 2015
Brazil became the first South American country Monday to authorize the world's first-ever dengue fever vaccine, which its French manufacturer says has the potential to save hundreds of lives here.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.